In summary, in addition to confirmation of RET-positive lung cancer heterogeneous genotypes and immunotypes, we first reported that patients with concurrent TP53 mutations or high TCR repertoire diversity have relatively unfavorable outcomes. Here, TP53 is linked to lung carcinoma.